Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2007 | 4.11 Million USD | -22.71% |
| 2006 | 5.32 Million USD | 115.12% |
| 2005 | 2.47 Million USD | 938.24% |
| 2004 | 238.53 Thousand USD | -95.8% |
| 2003 | 5.68 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 1999 | 7.57 Million USD | -18.78% |
| 1998 | 9.32 Million USD | -6.37% |
| 1997 | 9.95 Million USD | 61.34% |
| 1996 | 6.17 Million USD | 50.55% |
| 1995 | 4.1 Million USD | 141.18% |
| 1994 | 1.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2007 FY | 4.11 Million USD | -22.71% |
| 2007 Q1 | 3.3 Million USD | -37.98% |
| 2007 Q3 | 3.91 Million USD | 7.93% |
| 2007 Q2 | 3.62 Million USD | 9.78% |
| 2007 Q4 | 4.11 Million USD | 5.18% |
| 2006 Q4 | 5.32 Million USD | 16.74% |
| 2006 FY | 5.32 Million USD | 115.12% |
| 2006 Q1 | 3.06 Million USD | 23.78% |
| 2006 Q3 | 4.56 Million USD | 19.01% |
| 2006 Q2 | 3.83 Million USD | 25.09% |
| 2005 Q1 | 710.47 Thousand USD | 197.84% |
| 2005 FY | 2.47 Million USD | 938.24% |
| 2005 Q4 | 2.47 Million USD | 31.8% |
| 2005 Q3 | 1.87 Million USD | 25.49% |
| 2005 Q2 | 1.49 Million USD | 110.76% |
| 2004 Q1 | 6.59 Million USD | 16.07% |
| 2004 Q3 | 34.21 Thousand USD | -99.53% |
| 2004 Q4 | 238.53 Thousand USD | 597.26% |
| 2004 FY | 238.53 Thousand USD | -95.8% |
| 2004 Q2 | 7.22 Million USD | 9.53% |
| 2003 Q3 | 230.83 Thousand USD | -73.57% |
| 2003 FY | 5.68 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | 873.21 Thousand USD | 0.0% |
| 2003 Q4 | 5.68 Million USD | 2360.8% |
| 2002 FY | - USD | 0.0% |
| 2000 Q2 | 7.36 Million USD | -1.57% |
| 2000 Q1 | 7.47 Million USD | -1.24% |
| 1999 FY | 7.57 Million USD | -18.78% |
| 1999 Q3 | 7.64 Million USD | 0.0% |
| 1999 Q4 | 7.57 Million USD | -0.99% |
| 1998 FY | 9.32 Million USD | -6.37% |
| 1997 Q1 | 6.5 Million USD | 5.31% |
| 1997 FY | 9.95 Million USD | 61.34% |
| 1996 Q1 | 4 Million USD | -2.44% |
| 1996 FY | 6.17 Million USD | 50.55% |
| 1996 Q3 | 6.1 Million USD | 32.61% |
| 1996 Q2 | 4.6 Million USD | 15.0% |
| 1996 Q4 | 6.17 Million USD | 1.19% |
| 1995 Q2 | 2.7 Million USD | 17.39% |
| 1995 FY | 4.1 Million USD | 141.18% |
| 1995 Q1 | 2.3 Million USD | 35.29% |
| 1995 Q3 | 3.3 Million USD | 22.22% |
| 1995 Q4 | 4.1 Million USD | 24.24% |
| 1994 FY | 1.7 Million USD | 0.0% |
| 1994 Q3 | -800 Thousand USD | 0.0% |
| 1994 Q4 | 1.7 Million USD | 312.5% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 90.377% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -561.675% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1749.717% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 20278.479% |
| Qrons Inc. | 351.42 Thousand USD | -1071.801% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1250.172% |
| Skye Bioscience, Inc. | -5.72 Million USD | 171.976% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 165.319% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 314452.977% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 90.519% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -20627.961% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 27.094% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 73.875% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -924.769% |
| SQZ Biotechnologies Company | -36.23 Million USD | 111.364% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -83.657% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -344.142% |
| Mesoblast Limited | 55.85 Million USD | 92.628% |
| Marizyme, Inc. | 18.56 Million USD | 77.823% |
| Genus plc | 190.6 Million USD | 97.839% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -84.183% |
| Pharming Group N.V. | 109.8 Million USD | 96.25% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -378.706% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -239.243% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -505.592% |
| ContraFect Corporation | -6.02 Million USD | 168.338% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -2958.567% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -256.406% |
| IMV Inc. | 7.67 Million USD | 46.314% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 25.153% |
| MultiCell Technologies, Inc. | 90.04 USD | -4573449.534% |
| ONE Bio Corp. | 9.04 Million USD | 54.447% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 661.056% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 68.191% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -201.032% |
| Q BioMed Inc. | 4.06 Million USD | -1.429% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 86.522% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -308.649% |
| Biomind Labs Inc. | 711.4 Thousand USD | -478.86% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 93.198% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -105.964% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 67.844% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1044.818% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2845.57% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -87.015% |
| GB Sciences, Inc. | 1.74 Million USD | -135.677% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2340.638% |
| HST Global, Inc. | 96.79 Thousand USD | -4154.465% |
| CSL Limited | 10.52 Billion USD | 99.961% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1896.937% |
| Halberd Corporation | 144.72 Thousand USD | -2745.492% |
| Enzolytics Inc. | 981.65 Thousand USD | -319.498% |
| Agentix Corp. | 37.63 Thousand USD | -10843.169% |
| Resverlogix Corp. | 6.45 Million USD | 36.165% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 711.81% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.203% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 108.76% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 41.762% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -52.034% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 146.584% |
| AVAX Technologies, Inc. | -5.9 Million USD | 169.759% |
| Zenith Capital Corp. | 10.06 Thousand USD | -40818.362% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.388% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1954.574% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -72.589% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2403.221% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 22580.751% |
| Kadimastem Ltd | -253.1 Thousand USD | 1727.022% |
| Helix BioMedix, Inc. | -2.57 Million USD | 260.232% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 79.69% |
| BioStem Technologies, Inc. | 4.47 Million USD | 7.916% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1946.182% |
| LadRx Corporation | -2.03 Million USD | 302.214% |
| Cell Source, Inc. | 9.23 Million USD | 55.394% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -548.337% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -548.337% |
| NovAccess Global Inc. | 2.17 Million USD | -89.033% |
| Affymax, Inc. | -5.59 Million USD | 173.576% |
| Itoco Inc. | 228.3 Thousand USD | -1703.738% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2928.204% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 16.925% |
| Mobile Lads Corp. | 484.23 Thousand USD | -750.424% |
| CytoDyn Inc. | 20.26 Million USD | 79.676% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 636579.753% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 44531.085% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 46.561% |
| SYBLEU INC | 473.71 Thousand USD | -769.306% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 7.606% |
| International Stem Cell Corporation | 2.59 Million USD | -58.997% |
| Bioxytran, Inc. | 1.89 Million USD | -116.862% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6498.023% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -88.822% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -19.919% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 51.853% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -433.004% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 429.442% |
| Neutra Corp. | 52.18 Thousand USD | -7790.9% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 265.449% |
| PureTech Health plc | -167.19 Million USD | 102.463% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1781.458% |
| IXICO plc | -4.44 Million USD | 192.653% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 68.848% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 92.492% |
| CSL Limited | 10.52 Billion USD | 99.961% |
| Cellectis S.A. | -43.81 Million USD | 109.398% |